ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cemiplimab

Also written as “Cemiplimab”, “REGN2810” and “REGN2810/chemo/ipi”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Basal Cell · Squamous Cell Carcinoma of Head and Neck · Neoplasm Metastasis, led by 7 companies.

Drug pageCemiplimab: every studyMany companies study it; this page follows only the 42 they lead. All 135 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Mar 3, 201742 company-led studies, 18 open or runningNext primary completion: Mar 22, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticalsits history only3516 open or runningphase 3since Mar 3, 2017Feb 2, 2015Mar 22, 2027phase 3 · NCT06246916
BioNTechits history only20 open or runningphase 2since Apr 21, 2020Apr 21, 2020none ahead
Maia Biotechnology11 open or runningphase 3since Mar 20, 2025Mar 20, 2025Jul 31, 2027phase 3 · NCT06908304
Merck KGaA, Darmstadt, Germanyits history only10 open or runningphase 2since May 22, 2023May 22, 2023none ahead
Sanofiits history only10 open or runningphase 2since Jun 19, 2017Jun 19, 2017none ahead
SillaJenits history only10 open or runningphase 2since Sep 19, 2017Sep 19, 2017none ahead
Vyriadits history only11 open or runningphase 2since Feb 25, 2020Feb 25, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Maia Biotechnology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named cemiplimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, REGN2810
  2. Mar 20, 2025First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06908304 · 300 planned · Poland, Romania, Taiwan and more

Ahead

  1. Jul 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06908304

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The one study Maia Biotechnology leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06908304Carcinoma, Non-Small-Cell Lung · Poland, Romania, Taiwan and more3RecruitingJul 31, 2027300

How it is read

Names in the registry

  • “Cemiplimab”, 23 entries
  • “cemiplimab”, 9 entries
  • “REGN2810”, 4 entries
  • “REGN2810/chemo/ipi”, 2 entries
  • “Fianlimab+cemiplimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.